Valuation: Tengion, Inc.

Market Cap 1L 96.23T 88.7T 83.04T 2L 1.04Cr 2L 10.66L 4L 51.17L 4L 4L 1.77Cr P/E 2012
-0.14x
P/E 2013 -0.05x
Enterprise Value 55.52L 48.68L 44.87L 42.01L 78.77L 52Cr 80.41L 5.39Cr 2.09Cr 26Cr 2.08Cr 2.04Cr 90Cr EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
Change 5-day change 1-year change 3-year change Capi.($)
+3.15%+7.08%-33.84%-38.11% 57Cr
+11.25%+6.71%+191.99% - 41Cr
+0.60%+1.83%+62.93%+114.10% 13Cr
-3.73%-11.21%-39.96%+2.20% 12Cr
Average +2.82%+0.58%+45.28%+26.07% 30.73Cr
Weighted average by Cap. +4.91%+4.25%+51.29%-7.97%

Financials

2012 2013
Net sales - -
Net income -1.69Cr -1.48Cr -1.37Cr -1.28Cr -2.4Cr -159.7Cr -2.45Cr -16Cr -6.36Cr -79Cr -6.36Cr -6.22Cr -273.68Cr -1.89Cr -1.66Cr -1.53Cr -1.43Cr -2.69Cr -178.54Cr -2.74Cr -18Cr -7.11Cr -88Cr -7.11Cr -6.95Cr -305.98Cr
Net Debt 37.33L 32.73L 30.17L 28.25L 52.97L 35Cr 54.07L 3.63Cr 1.4Cr 17Cr 1.4Cr 1.37Cr 60Cr 54.42L 47.72L 43.98L 41.18L 77.21L 51Cr 78.82L 5.29Cr 2.05Cr 25Cr 2.04Cr 2Cr 88Cr
Logo Tengion, Inc.
Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Employees
-